[Role of plasminogen activators in cancer dissemination. Clinical perspectives].
Alonso
D F
DF
Instituto de Oncología Angel H. Roffo, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Bal de Kier Joffé
E
E
D000818:Animals; D014408:Biomarkers, Tumor / Q000097:blood; D005109:Extracellular Matrix / Q000502:physiology; D005342:Fibrinolysis; D006801:Humans; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D009362:Neoplasm Metastasis / Q000503:physiopathology*; D009363:Neoplasm Proteins / Q000097:blood / Q000502:physiology*; D009374:Neoplasms, Experimental / Q000097:blood / Q000473:pathology; D009360:Neoplastic Cells, Circulating; D010960:Plasminogen Activators / Q000097:blood / Q000502:physiology*; D011379:Prognosis; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator
Rol de los activadores del plasminógeno en la diseminación del cáncer.